Ceribell Reports First Quarter 2026 Financial Results
Ceribell, Inc. reported a strong first quarter for 2026 with revenue of $26.5 million, a 29% increase from the previous year. The company is focused on transforming seizure management and recently launched offerings for neonates and pediatrics. Despite increased operating expenses and a net loss of $19.7 million, Ceribell raised its full-year revenue guidance to a range of $112 million to $116 million.
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) — CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the first quarter ended March 31, 2026.